Home » Posts tagged 'feedback plc' (Page 2)
Tag Archives: feedback plc
Feedback #FDBK – Trevor Brown shareholding
Feedback announces that it has been advised by Trevor Brown that following recent share sales, he is now beneficially interested in 26,539,111 ordinary shares of 0.25p each, representing 10.77 per cent of the issued ordinary shares of the Company.
For further information, please contact:
|
Feedback plc Lara Mott, Investor Relations |
Tel: 01954 718072 |
|
Allenby Capital Limited (Nominated Adviser and Joint Broker) |
Tel: 020 3328 5656 |
|
Northland Capital Partners Ltd (Joint Broker) |
Tel: 020 3861 6625 |
|
Peterhouse Corporate Finance Ltd (Joint Broker) |
Tel: 020 7469 0936 |
Brand CEO Alan Green talks Feedback #FDBK, Petrofac #PFC & Prairie Mining #PDZ on VOX Markets podcast
Brand CEO Alan Green talks Feedback #FDBK, Petrofac #PFC & Prairie Mining #PDZ with Justin Waite on the VOX Markets podcast. The interview starts at 13 minutes in.
Feedback Plc #FDBK – Holdings in Company
TR-1: Standard form for notification of major holdings
|
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i |
||||||
|
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: |
Feedback plc |
|||||
|
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) |
||||||
|
Non-UK issuer |
||||||
|
2. Reason for the notification (please mark the appropriate box or boxes with an “X”) |
||||||
|
An acquisition or disposal of voting rights |
X |
|||||
|
An acquisition or disposal of financial instruments |
||||||
|
An event changing the breakdown of voting rights |
||||||
|
Other (please specify)iii: |
||||||
|
3. Details of person subject to the notification obligationiv |
||||||
|
Name |
Jonathan David Selby Cranston |
|||||
|
City and country of registered office (if applicable) |
||||||
|
4. Full name of shareholder(s) (if different from 3.)v |
||||||
|
Name |
||||||
|
City and country of registered office (if applicable) |
||||||
|
5. Date on which the threshold was crossed or reachedvi: |
28/12/17 |
|||||
|
6. Date on which issuer notified (DD/MM/YYYY): |
28/12/17 |
|||||
|
7. Total positions of person(s) subject to the notification obligation |
||||||
|
% of voting rights attached to shares (total of 8. A) |
% of voting rights through financial instruments |
Total of both in % (8.A + 8.B) |
Total number of voting rights of issuervii |
|||
|
Resulting situation on the date on which threshold was crossed or reached |
4.05 |
4.05 |
246,416,584 |
|||
|
Position of previous notification (if applicable) |
3.24 |
3.24 |
246,416,584 |
|||
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii |
|||||||||
|
A: Voting rights attached to shares |
|||||||||
|
Class/type of ISIN code (if possible) |
Number of voting rightsix |
% of voting rights |
|||||||
|
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
||||||
|
ord 0.25p |
10,000,000 |
4.05 |
|||||||
|
SUBTOTAL 8. A |
10,000,000 |
4.05 |
|||||||
|
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) |
|||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Number of voting rights that may be acquired if the instrument is exercised/converted. |
% of voting rights |
|||||
|
SUBTOTAL 8. B 1 |
|||||||||
|
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) |
|||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Physical or cash settlementxii |
Number of voting rights |
% of voting rights |
||||
|
SUBTOTAL 8.B.2 |
|||||||||
|
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) |
||||
|
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii |
X |
|||
|
Full chain of controlled undertakings through which the voting rights and/or the |
||||
|
Namexv |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
|
|
10. In case of proxy voting, please identify: |
||||
|
Name of the proxy holder |
||||
|
The number and % of voting rights held |
||||
|
The date until which the voting rights will be held |
||||
|
11. Additional informationxvi |
||||
|
Place of completion |
UK |
|
Date of completion |
28/12/17 |
Feedback Plc #FDBK – Holding in Company
Feedback announces that it has been advised by Trevor Brown that following share sales in the last few days, he is now beneficially interested in 30,929,111 ordinary shares of 0.25p each, representing 12.55 per cent of the issued ordinary shares of the Company.
For further information, please contact:
|
Feedback plc Lara Mott, Investor Relations |
Tel: 01954 718072 |
|
Allenby Capital Limited (Nominated Adviser and Joint Broker) |
Tel: 020 3328 5656 |
|
Northland Capital Partners Ltd (Joint Broker) |
Tel: 020 3861 6625 |
|
Peterhouse Corporate Finance Ltd (Joint Broker) |
Tel: 020 7469 0936 |
Feedback #FDBK – Result of AGM
Feedback #FDBK – Result of Annual General Meeting
The Company announces that at the annual general meeting of the Company held earlier today, all resolutions were duly passed.
For further information, please contact:
|
Feedback plc Lara Mott, Investor Relations |
Tel: 01954 718072 |
|
Allenby Capital Limited (Nominated Adviser and Joint Broker) |
Tel: 020 3328 5656 |
|
Northland Capital Partners Ltd (Joint Broker) |
Tel: 020 3861 6625 |
|
Peterhouse Corporate Finance Ltd (Joint Broker) |
Tel: 020 7469 0936 |
Feedback Plc #FDBK – Holdings in Company
TR-1: Standard form for notification of major holdings
|
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i |
||||||
|
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: |
Feedback plc |
|||||
|
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) |
||||||
|
Non-UK issuer |
||||||
|
2. Reason for the notification (please mark the appropriate box or boxes with an “X”) |
||||||
|
An acquisition or disposal of voting rights |
X |
|||||
|
An acquisition or disposal of financial instruments |
||||||
|
An event changing the breakdown of voting rights |
||||||
|
Other (please specify)iii: |
||||||
|
3. Details of person subject to the notification obligationiv |
||||||
|
Name |
Jonathan David Selby Cranston |
|||||
|
City and country of registered office (if applicable) |
||||||
|
4. Full name of shareholder(s) (if different from 3.)v |
||||||
|
Name |
||||||
|
City and country of registered office (if applicable) |
||||||
|
5. Date on which the threshold was crossed or reachedvi: |
21/11/17 |
|||||
|
6. Date on which issuer notified (DD/MM/YYYY): |
22/11/17 |
|||||
|
7. Total positions of person(s) subject to the notification obligation |
||||||
|
% of voting rights attached to shares (total of 8. A) |
% of voting rights through financial instruments |
Total of both in % (8.A + 8.B) |
Total number of voting rights of issuervii |
|||
|
Resulting situation on the date on which threshold was crossed or reached |
3.24 |
3.24 |
246,416,584 |
|||
|
Position of previous notification (if applicable) |
||||||
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii |
|||||||||
|
A: Voting rights attached to shares |
|||||||||
|
Class/type of ISIN code (if possible) |
Number of voting rightsix |
% of voting rights |
|||||||
|
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
||||||
|
ord 0.25p |
8,000,000 |
3.24 |
|||||||
|
SUBTOTAL 8. A |
8,000,000 |
3.24 |
|||||||
|
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) |
|||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Number of voting rights that may be acquired if the instrument is exercised/converted. |
% of voting rights |
|||||
|
SUBTOTAL 8. B 1 |
|||||||||
|
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) |
|||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Physical or cash settlementxii |
Number of voting rights |
% of voting rights |
||||
|
SUBTOTAL 8.B.2 |
|||||||||
|
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) |
||||
|
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii |
X |
|||
|
Full chain of controlled undertakings through which the voting rights and/or the |
||||
|
Namexv |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
|
|
10. In case of proxy voting, please identify: |
||||
|
Name of the proxy holder |
||||
|
The number and % of voting rights held |
||||
|
The date until which the voting rights will be held |
||||
|
11. Additional informationxvi |
||||
|
Place of completion |
Lymm, Cheshire, UK |
|
Date of completion |
22/11/17 |
Feedback #FDBK – Presentation at RSNA 2017
Feedback plc (AIM: FDBK), the specialist medical imaging technology company, announces that Dr Balaji Ganeshan will be presenting at the 103rd Scientific Assembly and Annual Meeting of the Radiological Society of North America (“RSNA 2017”) taking place from 26 November to 1 December 2017 in Chicagbalajio (IL), USA.
The details for the oral presentation on the study undertaken at the Institute of Nuclear Medicine, University College London, UK are as follows:
Date and session time: Wednesday 29 November at 15:00 – 16:00 CST
Title: Texture Analysis of 68Ga-DOTATATE Positron Emission Tomography and Computed Tomography Images as a Prognostic Biomarker in Adults with Neuro-Endocrine Cancers Treated with 177Lu-DOTATATE
Abstract number: SSM13-06
Session: Molecular Imaging (Analysis and Quantification)
Room: S504C
Presenter: Balaji Ganeshan, PhD
Two additional papers co-authored by Dr Balaji Ganeshan will be presented at RSNA 2017; one by Seoul National University and University College London focused on liver cancer (abstract SSK07-05), and one by Cambridge University, the University of Rome and University College London focused on ischemic stroke (abstract SSQ15-02). Overall, RSNA 2017 is expected to include at least 18 scientific paper presentations featuring TexRAD® Computed Tomography Texture Analysis (CTTA) and Magnetic Resonance Texture Analysis (MRTA), many of which have won awards in this year’s RSNA categories. Further information can be found at https://rsna2017.rsna.org/program.
Dr Balaji Ganeshan, Director of New Business at Feedback plc, said: “RSNA is the premier global event for radiologists and the increasing focus on our TexRAD® technology is encouraging. As seen in previous years, our renowned customers will highlight multiple TexRAD® presentations across various disease indications, further emphasising the significance of our technology across the healthcare industry. We look forward to discussing TexRAD® with this year’s RSNA delegates.”
TexRAD® is the Company’s patented quantitative image texture analysis technology for diagnostic radiological scans. The technology has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer, or other disease indications, and is currently installed in over 40 of the world’s leading research institutions across Europe, North America, Asia and Australasia. By analysing the texture features in computerised tomography (CT) scans, magnetic resonance images (MRI) and positron emission tomography scans (PET/CT), TexRAD®‘s quantitative imaging capabilities provide clinicians with additional, visually imperceptible information to make better decisions in order to improve patient outcomes.
TexRAD® research to date has shown great potential in many different oncological and non-oncological sites. In particular, the papers being presented at RSNA 2017 focus on liver, pancreatic, kidney, cervical, oral, genitourinary, head & neck, thyroid, neuroendocrine and endometrial cancers, as well as gastrointestinal stromal tumours, gliomas, thymic-epithelial neoplasms and carotid-plaques. On 20 November 2017, Feedback announced the CE marked release of TexRAD® Lung, a “software only” Class 1 medical device, to help advance lung cancer diagnosis. Further information on the TexRAD®technology can be found at www.texrad.com.
– Ends –
Notes to editors
About Feedback plc
Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD®, the Company’s patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 40 of the world’s leading research institutions across Europe, North America, Asia and Australasia. The Cadranplatform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system (PACS) to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data. Visit www.fbk.com.
For further information, please contact:
|
Feedback plc Dr Alastair Riddell, Chairman Lara Mott, Investor Relations
|
Tel: 01954 718072 hello@fbk.com |
Round the Clock Trader today features Dr David Paul of VectorVest and Brand CEO Alan Green
Round the Clock Trader today is hosted by Simon Campbell and Zak Mir. Dr David Paul of VectorVest talks market timing, Games Workshop #GAW, Prudential #PRU, Volex #VLX. His slot is 20 minutes in. Brand CEO Alan Green talks Feedback #FDBK, Advanced Oncotherapy #AVO and Petrofac #PFC. His slot is 52 minutes 30 seconds in .
Feedback Plc (FDBK) – Trevor Brown shareholding
Feedback announces that it has been advised by Trevor Brown that following share sales last week, he is now beneficially interested in 37,929,111 ordinary shares of 0.25p each, representing 15.39 per cent of the issued ordinary shares of the Company.
For further information, please contact:
|
Feedback plc Lara Mott, Investor Relations |
Tel: 01954 718072 |
|
Allenby Capital Limited (Nominated Adviser and Joint Broker) |
Tel: 020 3328 5656 |
|
Northland Capital Partners Ltd (Joint Broker) |
Tel: 020 3861 6625 |
|
Peterhouse Corporate Finance Ltd (Joint Broker) |
Tel: 020 7469 0936 |
Feedback plc #FDBK – First CE marked release of TexRAD® technology
Feedback plc (AIM: FDBK), the specialist medical imaging technology company, announces the first CE marked release of TexRAD®; the Company’s patented quantitative image texture analysis technology for diagnostic radiological scans.
TexRAD® has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 40 of the world’s leading research institutions across Europe, North America, Asia and Australasia. Feedback’s subsidiary company, Cambridge Computed Imaging Ltd,
has affixed a CE mark to “TexRAD® Lung”; a “software only” Class 1 medical device providing additional information for the interpretation of computerised tomography (CT) and positron emission tomography (PET) scans of patients with lung cancer. The CE mark confirms that TexRAD® Lung meets the requirements of the Medical Device Directive (MDD – 93/42EEC) ensuring the technology satisfies the quality, safety and performance standards for medical devices in the European Union (EU).
Lung cancer has been the most common cancer in the world for several decades, estimated at 13% of all cancer diagnoses globally. It is also the most common cause of death from cancer worldwide, estimated to be responsible for nearly one in five. In the EU alone there are approximately 417,000 new cases of lung cancer every year. Radiologists are under significant pressure due to increasing patient numbers, more examinations required per patient and the need for earlier diagnosis. By analysing the texture features in CT scans, TexRAD®‘s quantitative imaging capabilities provide clinicians with additional information to make better decisions in order to improve patient outcomes.
Dr Alastair Riddell, Chairman at Feedback plc, said: “TexRAD® Lung is our first TexRAD® product with a CE mark which represents a significant accomplishment. This development will expedite TexRAD®‘s clinical use in the treatment of lung cancer across the EU, expand its market presence and support the Company’s ongoing commercial discussions for the technology. We expect that the rigorous regulatory review required for the CE mark will pave the way for TexRAD®‘s clinical use worldwide and we are now investigating the clinical application of TexRAD®in liver cancer and chronic obstructive pulmonary disease (COPD). By arming clinicians with disease-specific tools, we believe this technology has the potential to transform radiological decision making.”
– Ends –
Notes to editors
About Feedback plc
Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD®, the Company’s patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 40 of the world’s leading research institutions across Europe, North America, Asia and Australasia. The Cadran platform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system (PACS) to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data. Visit www.fbk.com.
About CE marking
CE marking (and compliance with the directive) is legally required before placing a device on the market in the EU. An appropriate quality management system and the preparation of a technical file are requirements for CE marking. The CE technical file is a comprehensive description of the device intended to demonstrate compliance with the Medical Device Directive and contains extensive documentation on the use, design, risk assessment, testing, clinical evaluation and manufacture of the device.
For further information, please contact:
|
Feedback plc Dr Alastair Riddell, Chairman Lara Mott, Investor Relations
|
Tel: 01954 718072 hello@fbk.com |
|
Allenby Capital Limited (Nominated Adviser and Joint Broker) David Worlidge / James Thomas
|
Tel: 020 3328 5656 |
|
Northland Capital Partners Ltd (Joint Broker) Patrick Claridge / David Hignell / John Howes
|
Tel: 020 3861 6625 |
|
Peterhouse Corporate Finance Ltd (Joint Broker) Lucy Williams / Duncan Vasey |